Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) has provided a corporate and operational update highlighting continued progress across its clinical development program, manufacturing activities, regulatory initiatives, financing strategy and commercialization efforts. The company reported positive six-month results from its First-in-Human (FIH) study, which support advancement to Group Two clinical surgeries. Manufacturing of a redesigned next-generation accommodating intraocular lens, referred to as the Ocumetics Lens, has commenced in Germany in preparation for the planned Group Two surgeries, which remain on track for Q3 2026 in Mexico City.
The six-month follow-up data from Group One patients continues to demonstrate encouraging safety and performance outcomes. The surgical team reported successful implantation procedures and favorable post-operative outcomes. The study continues to achieve its primary objectives related to safety, lens delivery and distance vision correction. Anecdotally, patients have reported meaningful improvements in vision and quality of life, including one individual previously considered legally blind who is now qualified to drive. These positive clinical outcomes have provided the foundation necessary for Ocumetics to advance to the second group of its FIH study.
Ocumetics has completed development of its next-generation solid-state accommodating intraocular lens, representing years of research, engineering and product refinement. The redesigned lens incorporates significant advancements intended to improve manufacturability, surgical handling, long-term reliability and accommodative performance while simplifying future commercial production. Expected benefits include enhanced accommodative performance, simplified lens architecture with a one-piece design, improved manufacturing consistency, elimination of internal interface materials (no air, water or oil), optimized surgical implantation characteristics, improved compatibility with the redesigned lens delivery system, and greater scalability for commercial manufacturing.
To support completion of its FIH clinical study and prepare for subsequent regulatory submissions, the company has launched a financing initiative intended to fund the next phase of clinical development while supporting manufacturing, regulatory and commercialization activities. Proceeds are expected to be used to complete Group Two FIH surgeries in Mexico City, finalize manufacturing and quality verification of clinical lenses, complete sterilization and packaging activities, advance regulatory and quality assurance programs, and continue strategic partnership and commercialization initiatives.
The company continues to engage with several of the world's leading ophthalmic organizations regarding potential strategic partnerships and commercialization opportunities. To date, management has met with representatives from four of the world's seven largest ophthalmic companies to introduce the Ocumetics technology platform. Based on encouraging feedback received during these meetings, several organizations have expressed interest in reviewing additional clinical data following completion of Group Two surgeries. Follow-up discussions are tentatively scheduled for early Q4 2026 following the availability of Group Two one-month patient results.
All regulatory requirements necessary to proceed to Group Two patient enrollment have been successfully completed. Working closely with its clinical investigators, ethics committees and regulatory consultants, the company has completed the regulatory processes required to advance the study. Upon completion of manufacturing and product release activities, patient recruitment and surgical scheduling will commence. Group Two patients are expected to receive the redesigned Ocumetics Lens delivered with the company's updated lens delivery system.
Management believes that positive one-month results of the Group Two patients will represent another meaningful value-creation milestone for Ocumetics as the company advances toward its larger clinical studies, future regulatory submissions and eventual commercialization. With positive six-month clinical data, completion of the next-generation lens design, manufacturing underway, regulatory milestones achieved and strategic commercialization discussions continuing, Ocumetics believes it is well positioned to execute the next phase of its clinical development strategy.
